CHRONIC KIDNEY DISEASE - STAGE V

This study tested the long-term safety of a drug called MCI-196 (Colestilan) in 116 adults with stage 5 chronic kidney disease who are on dialysis and have high phosphorus levels. Participants took flexible doses of the drug for 52 weeks. The main goal was to see how many side ef…

This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common …

This Phase 3 trial tested MCI-196, a drug that binds phosphorus and lowers cholesterol, in 642 adults on dialysis with chronic kidney disease. Participants received either MCI-196 or a placebo for 12 weeks. The goal was to see if the drug could safely reduce both serum phosphorus…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their phosphorus and cholesterol. The goal was to help contr…

This study tested whether a guided mindfulness meditation program, practiced during dialysis sessions, could reduce anxiety and improve spiritual well-being in people with chronic kidney disease. Fifty-eight adults on hemodialysis were randomly assigned to either the meditation g…

This study looked at 58 adults on hemodialysis to understand how the mix of bacteria in their gut relates to waste products in their blood. Researchers measured different types of gut bacteria and chemicals they produce, like short-chain fatty acids and uremic toxins. The goal wa…

This completed study looked at fat tissue in 23 men with advanced chronic kidney disease (stage V) who were not on dialysis. Researchers compared their fat cells to those of healthy men to understand why kidney disease causes problems like weight loss and insulin resistance. Fat …